Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

This is a Phase 1, multicenter, open-label, PK, safety and tolerability study of oritavancin
in pediatric patients (<18 years of age) with suspected or diagnosed Gram-positive bacterial
infections or pediatric patients requiring peri-operative prophylactic antibiotics.
Approximately 52 patients will be enrolled at 5-10 US centers. This study will include 5 age
cohorts and patients will be entered in a stepwise approach starting with the older age
cohort (12-<18 years). The starting dose will be IV oritavancin 15 mg/kg. The safety,
tolerability and PK data will be reviewed at the completion of each cohort to ensure safety
and determine the appropriate dose for the next age cohort. At least 8 patients will be
enrolled in each cohort except for the birth to <3 month age cohort which will have at least
16 patients enrolled. Three PK samples will be collected over 14 days. The safety follow-up
will complete with a 60-day phone call to the caregiver.

Inclusion Criteria:

- Males and females <18 years of age

- Neonates must be at least 34 weeks post-conception age

- Parent or legal guardian has given informed consent, as appropriate; and pediatric
patient has given verbal assent where appropriate.

- Suspected or diagnosed Gram positive bacterial infection for which the subject is
receiving standard antibiotic therapy; or peri-operative prophylactic use of
antibiotics

- Intravenous access to administer study drug

- The subject will be observed in the emergency room or hospital for at least 1 hour
after the study drug infusion is completed.

Exclusion Criteria:

- Septic shock or acute haemodynamic instability.

- History of immune-related hypersensitivity reaction to glycopeptides (such as
vancomycin, dalbavancin, televancin, or teicoplanin) or any of their excipients.

- Subjects who have taken vancomycin, telavancin, teicoplanin or other glycopeptide
within 24 hours of screening or who are anticipated to need these drugs within 48
hours after administration of study drug. Subjects who have taken dalbavancin are
excluded if taken within the previous 2 weeks or who are anticipated to need
dalbavancin within 48 hours after administration of study drug.

- Females who are of childbearing potential and unwilling to practice abstinence or use
at least two methods of contraception or female patients of childbearing who are
lactating or have a positive pregnancy test result at screening

- Males who are unwilling to practice abstinence or use an acceptable method of birth
control during the entire study period

- Any surgical or medical condition which, in the opinion of the investigator, would put
the patient at increased risk or is likely to interfere with study procedures or PK of
the study drug.

- Patients whom the investigator considers unlikely to adhere to the protocol, comply
with study drug administration, or complete the clinical study

- Treatment with investigational medicinal product or investigational device within 30
days (or 5 times the half-life of the investigational medicine, whichever is longer)
before enrollment and for the duration of the study.

- Any clinically significant disease or condition affecting a major organ system,
including but not limited to gastrointestinal, renal, hepatic, endocrinologic,
broncho-pulmonary, neurological, metabolic or cardiovascular disease.